Patients with hematological malignancies are at risk of severe COVID-19 and candidate to priority vaccination policies, preferably with a mRNA vaccine. In light of ethical considerations and strict indications of Health Authorities (HA), also patients with ongoing lymphodepleting therapy underwent vaccination. In Italy, the national plan against COVID-19 required to proceed as soon as possible with the vaccination of hematological patients in treatment with immunosuppressive or myelosuppressive drugs or within six months from the end of such treatment, and of stem cell transplanted patients after three months from transplant.
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas / Marchesi, F.; Pimpinelli, F.; Giannarelli, D.; Ronchetti, L.; Papa, E.; Falcucci, P.; Pontone, M.; Di Domenico, E. G.; di Martino, S.; Laquintana, V.; Mandoj, C.; Conti, L.; Cordone, I.; La Malfa, A.; Viggiani, C.; Renzi, D.; Palombi, F.; Romano, A.; Pisani, F.; Gumenyuk, S.; Di Bella, O.; Vujovic, B.; Morrone, A.; Ciliberto, G.; Ensoli, F.; Mengarelli, A.. - In: LEUKEMIA. - ISSN 0887-6924. - 36:2(2022), pp. 588-590. [10.1038/s41375-021-01418-8]
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
Marchesi F.;Pimpinelli F.;Pontone M.;Di Domenico E. G.;Laquintana V.;La Malfa A.;Viggiani C.;Di Bella O.;Ensoli F.;
2022
Abstract
Patients with hematological malignancies are at risk of severe COVID-19 and candidate to priority vaccination policies, preferably with a mRNA vaccine. In light of ethical considerations and strict indications of Health Authorities (HA), also patients with ongoing lymphodepleting therapy underwent vaccination. In Italy, the national plan against COVID-19 required to proceed as soon as possible with the vaccination of hematological patients in treatment with immunosuppressive or myelosuppressive drugs or within six months from the end of such treatment, and of stem cell transplanted patients after three months from transplant.| File | Dimensione | Formato | |
|---|---|---|---|
|
Marchesi_Impact_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
455.93 kB
Formato
Adobe PDF
|
455.93 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
